Evidence map›Paper›PMID 39951912›Full record

ReviewFrontiers in neuroendocrinology2025

Sex/gender differences in the clinical trajectory of Alzheimer's disease: Insights into diagnosis and cognitive reserve.

Sheina Emrani, Erin E Sundermann

Abstract readReview
In one paragraph

Review in Frontiers in neuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Elevated temporal tau PET predicts faster cognitive decline in women than men: A meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Pooled it
  2. Observational
  3. Article
  4. Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females.European journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Considerations in Alzheimer's Disease in Women.Current neurology and neuroscience reports · 2026
    Review
  6. Sex differences in brain glucose metabolism and Alzheimer's disease risk and progression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  7. Article
  8. System changes to empower primary care in Alzheimer's disease detection and care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Fecal short-chain fatty acids vary by sex and amyloid status.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sheina EmraniDepartment of Neurology, University of Pennsylvania, Dulles 3(rd) Floor, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Erin E SundermannDepartment of Psychiatry, University of California, San Diego, UCSD ACTRI Building, Office 2W517, USA. Electronic address: esundermann@health.ucsd.edu.

Funding

Sex Differences in the Clinical Expression of Alzheimer's Disease Neuropathology and Their Underlying Biological MechanismsR01AG074221 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUNDERMANN, ERIN ELIZABETH · 2021 to 2025
$2.7M
Cross-disciplinary training in translational neuroimaging of ADRDT32AG076411 · NIA · UNIVERSITY OF PENNSYLVANIA · PI JOHN A DETRE, MURRAY GROSSMAN · 2022 to 2026
$1.5M
NIA NIH HHS R01 AG074221NIA NIH HHS T32 AG076411
6 · The paper itself

Abstract

The two-times higher prevalence of Alzheimer's disease (AD) in females versus males is well-known; however, there are also sex/gender differences in clinical presentation and diagnostic accuracy that are less examined but equally important to understand in terms of improving early detection, intervention and disease tracking in each sex/gender. This review explores how these disparities in clinical presentation manifest across the AD continuum, with a focus on the earlier stages of preclinical AD and mild cognitive impairment (MCI). We summarize evidence indicating that female's verbal memory advantage may mask early cognitive decline, leading to delayed MCI diagnosis and limiting opportunities for early intervention. Conversely, females demonstrate steeper cognitive decline at later disease stages compared to males. These patterns align with the cognitive reserve theory, suggesting female's verbal memory strength may act as a domain-specific resilience factor. Lastly, this review emphasizes the need for sex-sensitive diagnostic tools to improve early detection accuracy and equity in clinical practice.

Indexed as

Alzheimer DiseaseCognitive DysfunctionCognitive ReserveSex CharacteristicsDisease ProgressionFemaleHumansMaleSex FactorsAlzheimer’s diseaseClinical presentationCognitive reserveDiagnostic accuracyMild Cognitive ImpairmentSex/genderVerbal memory

Identifiers

PMID39951912
PMCPMC13045642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.